Neuropeptide�Y upregulates Runx2 and osterix and enhances osteogenesis in mouse MC3T3‐E1 cells via an autocrine mechanism

Bo Zhang,Xiaolei Zhang,Juan Xiao,Xuguang Zhou,Yuan Chen,Chunzheng Gao
DOI: https://doi.org/10.3892/mmr.2020.11506
IF: 3.423
2020-09-14
Molecular Medicine Reports
Abstract:The neuropeptide Y (NPY) system is considered one of the primary neural signaling pathways. NPY, produced by osteoblasts and other peripheral tissues, is known to inhibit biological functions of osteoblasts. However, until recently, little was known of the autocrine mechanism by which NPY is regulated. To investigate this mechanism, overexpression plasmids and small interfering RNA (siRNA) targeting NPY were transfected into the MC3T3‑E1 cell line to observe its effects on osteogenesis. NPY overexpression was found to markedly enhance the osteogenic ability of MC3T3‑E1 cells by an autocrine mechanism, coincident with the upregulation of osterix and runt‑related transcription factor 2 (Runx2). Furthermore, NPY increased the activities of alkaline phosphatase (ALP) and osteocalcin (OCN) by upregulating their osteoblastic expression in vitro (as well as that of osterix and Runx2). Following transfection with NPY‑siRNA, the osteoblastic ability of MC3T3‑E1 cells was markedly decreased, and NPY deficiency inhibited the protein expression of osterix, Runx2, OCN and ALP in primary osteoblasts. Collectively, these results indicated that NPY played an important role in osteoblast differentiation by regulating the osterix and Runx2 pathways.
oncology,medicine, research & experimental
What problem does this paper attempt to address?